Company Analysis

Repligen Corporation (RGEN)

Nasdaq: RGEN · Biological Products, (No Diagnostic Substances) · Waltham, MA · filing with the SEC since 1995
Grade5.4
◀ Past 6.3● Present 6.4▶ Future 4.1

Who runs Repligen Corporation

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Loeillot Olivier
Chief Executive Officer. First filing Oct 2023, latest Oct 6, 2026, 7 filings in all.
Officers reporting now
7
of 15 people with a filing in the last fifteen months
Directors reporting now
8
22 people on the record since 2006
Officerssales are open-market, Oct 8, 2025 to Oct 8, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Douglass Brian RobbCHIEF PRODUCT OFFICERDec 2025Oct 8, 2026none
Loeillot OlivierChief Executive OfficerOct 2023Oct 6, 20269 · $7.7M
Garland Jason KCFOSep 2023Sep 28, 20262 · $200,000
Hughes ViolettaCHIEF ACCOUNTING OFFICERSep 2025Sep 2, 2026none
Bylund JamesChief Operating OfficerMar 2021Mar 23, 20261 · $300,000
Kuriyel RalfSenior VP, R&DMar 2018Mar 23, 2026none
Hunt AnthonyChief Executive OfficerMay 2014Mar 3, 202612 · $7.0M
Directorssales are open-market, Oct 8, 2025 to Oct 8, 2026
NameRoleFirst filingLatest filingSales, 12 months
Barthelemy NicolasdirectorJun 2014May 18, 2026none
Dawes Karen AdirectorSep 2006May 18, 20261 · $0.00
Eglinton Manner CarriedirectorJun 2020May 18, 2026none
Konstantinov KonstantindirectorMay 2022May 18, 2026none
Madaus Martin DdirectorFeb 2023May 18, 2026none
Mhatre RohindirectorMar 2020May 18, 2026none
Muir Glenn PdirectorSep 2015May 18, 2026none
Pax MargaretdirectorMar 2024May 18, 2026none
Earlier names on the record8, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton RGEN · research, not advice